A new prescription drug formulary in Ohio, along with several other measures, appears to have reduced the dosage of narotics for work comp injuries by 12% in a year-over-year comparison conducted by Ohio Bureau of Workers' Compensation. Costs were reduced by 15%, or $2.1 million.
Compare this to the early results from the Texas Closed Formulary - depending on the study you reference, the new rules have reduced initial opioid prescriptions for new injuries by anywhere from 50% to 67%. And the rules don't apply to legacy claims until September of 2013.
So, for those of you counting at home... that's two state-level formulary adoptions and two clearly favorable sets of early results.
Michael
On Twitter @PRIUM1
Michael Gavin, President of PRIUM, focuses on healthcare issues facing risk managers in the workers' compensation space and beyond. He places particular emphasis on the over-utilization of prescription drugs in the treatment of injured workers.
Monday, July 30, 2012
Thursday, July 26, 2012
Physicians for Responsible Opioid Prescribing: Get to Know This Organization
As we wage the daily battle against the over-utilization of opioids in workers' compensation, it's important to recognize an increasingly important ally in the physician community: Physicians for Responsible Opioid Prescribing (PROP).
Just this week, PROP led the way on a petition to the FDA to change the labels on opioid painkillers to prohibit their use for moderate pain, add a max daily dose, and only allow patients to take the drugs for 90 days unless they're being treated for cancer-related pain. This is a bold petition and an even bolder request, but PROP is as serious about this issue as they are credible.
PRIUM relies on the PROP web site for training materials, both for internal staff as well as our network of physician reviewers. The videos on the site are absolutely phenomenal and they help us to orient new employees and our physician partners to the seriousness of the issue, the complexities of dealing with the issue, and the dedication required to ensure positive clinical outcomes.
Dr. Andrew Kolodny is the President of PROP. He is working tirelessly to bring awareness and solutions to one of the great healthcare crises of our generation. He speaks at conferences, he engages with physician groups, he speaks to payers, and he writes editorials published in the NY Times. His message is consistent, credible, and critical. I've met Dr. Kolodny a few times (he even bailed me out when I was speaking at a conference and had technical issues trying to show a PROP video - he kindly stood up and delivered the message himself!). His passion for the appropriate use of prescription narcotics is powerful.
Get to know PROP. They're helping us in the payer/employer community every day. Let's find some ways we can help them.
Michael
On Twitter @PRIUM1
Just this week, PROP led the way on a petition to the FDA to change the labels on opioid painkillers to prohibit their use for moderate pain, add a max daily dose, and only allow patients to take the drugs for 90 days unless they're being treated for cancer-related pain. This is a bold petition and an even bolder request, but PROP is as serious about this issue as they are credible.
PRIUM relies on the PROP web site for training materials, both for internal staff as well as our network of physician reviewers. The videos on the site are absolutely phenomenal and they help us to orient new employees and our physician partners to the seriousness of the issue, the complexities of dealing with the issue, and the dedication required to ensure positive clinical outcomes.
Dr. Andrew Kolodny is the President of PROP. He is working tirelessly to bring awareness and solutions to one of the great healthcare crises of our generation. He speaks at conferences, he engages with physician groups, he speaks to payers, and he writes editorials published in the NY Times. His message is consistent, credible, and critical. I've met Dr. Kolodny a few times (he even bailed me out when I was speaking at a conference and had technical issues trying to show a PROP video - he kindly stood up and delivered the message himself!). His passion for the appropriate use of prescription narcotics is powerful.
Get to know PROP. They're helping us in the payer/employer community every day. Let's find some ways we can help them.
Michael
On Twitter @PRIUM1
Courage in Illinois: Doing the Right Thing on Repackaging
Illinois is working through a regulatory change that would cap the price of repackaged drugs at AWP + a dispensing fee. As I've previously argued, this is the right way to go about changing the practice of physician dispensing. By eliminating the financial incentive to dispense medications, but maintaining the physician's right to do so for the rare cases where an injured worker may truly benefit from getting scripts in the office, the state leaves all stakeholders with the right mix of incentives.
What's unique about Illinois, however, are the two votes that took place within the last few days. The Illinois Workers' Compensation Commission voted 9-1 to move ahead with revisions to drug repackaging rules in the state, despite a 4-3 vote from the medical advisory board NOT to proceed.
At the risk of appearing dramatic, I view this relatively small procedural victory as a potential tipping point in the legislative/regulatory landscape around drug repackaging and physician dispensing. Predictably, the insurance and employer community likes the new rule while the physician community is opposed. But in this case, the physician community said "no" and the WCC moved forward anyway. They did so because the evidence, data, and logic tells them this is the right thing to do.
Progress.
Michael
On Twitter @PRIUM1
What's unique about Illinois, however, are the two votes that took place within the last few days. The Illinois Workers' Compensation Commission voted 9-1 to move ahead with revisions to drug repackaging rules in the state, despite a 4-3 vote from the medical advisory board NOT to proceed.
At the risk of appearing dramatic, I view this relatively small procedural victory as a potential tipping point in the legislative/regulatory landscape around drug repackaging and physician dispensing. Predictably, the insurance and employer community likes the new rule while the physician community is opposed. But in this case, the physician community said "no" and the WCC moved forward anyway. They did so because the evidence, data, and logic tells them this is the right thing to do.
Progress.
Michael
On Twitter @PRIUM1
Tuesday, July 24, 2012
Drug Repackaging: WCRI and AHCS
From time to time, an important report is released that thoroughly covers a critical topic in our industry. And sometimes, others provide such thorough analysis that I find it difficult to add to what's already been said. Such is the case with WCRI's new report on physician dispensed repackaged drugs in work comp.
David DePaolo's overview of the report is excellent and he provides a well balanced view of the controversy this report has sparked.
Joe Paduda takes on the AHCS critique of the report. His rebuttal is spot on and contains important insights for policy makers that will surely confront AHCS as the legislative/regulatory process evolves on a state by state basis to address this issue.
Bottom line: The report is thorough, unbiased, data-driven, and eye-opening. The issue of physician dispensing of repackaged drugs is a major weak spot in many jurisdictions' work comp statutes and rules. A legislative/regulatory solution is needed and I think Connecticut's new rule provides an excellent template.
Michael
On Twitter @PRIUM1
David DePaolo's overview of the report is excellent and he provides a well balanced view of the controversy this report has sparked.
Joe Paduda takes on the AHCS critique of the report. His rebuttal is spot on and contains important insights for policy makers that will surely confront AHCS as the legislative/regulatory process evolves on a state by state basis to address this issue.
Bottom line: The report is thorough, unbiased, data-driven, and eye-opening. The issue of physician dispensing of repackaged drugs is a major weak spot in many jurisdictions' work comp statutes and rules. A legislative/regulatory solution is needed and I think Connecticut's new rule provides an excellent template.
Michael
On Twitter @PRIUM1
Thursday, July 19, 2012
Suboxone: Our View
I'm seeing and hearing a lot of advertising for www.turntohelp.com here in the Atlanta area. I don't know if it's a nationwide push or unique to our market, but the ad buy here is significant.
Of course, the site is sponsored by Reckitt Benckiser, makers of Suboxone - a drug "indicated for maintenance treatment of opioid dependence as part of a complete treatment plan to include counseling and psychological support."
On the one hand, it's difficult to justify the suggestion that the solution to dependence on pills... is more pills. Different pills, clearly, but still a pharmacological solution to a pharmacological (and psychological) problem. Welcome to 21st century medicine. Also troubling is how often we see Suboxone introduced without the weaning of the other opioid medications. We see this on cases PRIUM reviews. Sometimes, the doctor is choosing to prescribe Suboxone for chronic pain management (which represents off-label use, but is the doctor's right to do). Sometimes, the doctor intends to wean the other medications, but finds the patient unable or unwilling to participate in the weaning process. Why Suboxone isn't immediately discontinued in this scenario isn't clear, but we see if often enough that PRIUM's physician reviewers are clearly concerned about the appropriate use of this medication.
On the flip side, we do see cases here at PRIUM where Suboxone is used appropriately and successfully. And I personally know a few people that have been weaned off of very high dose narcotics successfully through the use of Suboxone.
Bottom line: If you see Suboxone on a claim, make absolutely sure that the physician is DATA 2000 certified and that the drug is being used appropriately. Close monitoring is key to a successful outcome.
Back to the web site for moment: www.turntohelp.com is actually a tremendous resource. Clearly, RB put a lot of time, effort, and study into crafting an easy to navigate, informative, balanced approach to the treatment of opioid dependence. Candidly, it took me about 10 minutes before I ended up on the Suboxone web site (I thought it would take less than a minute). The information on the site emphasizes the need for counseling and psychological support and goes to great lengths to discuss all available treatment options. RB is clearly not going for a direct sell of Suboxone, but rather counting on the fact that if more people seek treatment, some percentage may end up on Suboxone. There are plenty of other sites you can leverage to get the same information, but I've not found any as well organized or easy to navigate.
Certainly open to recommendations, though...
Michael
On Twitter @PRIUM1
Of course, the site is sponsored by Reckitt Benckiser, makers of Suboxone - a drug "indicated for maintenance treatment of opioid dependence as part of a complete treatment plan to include counseling and psychological support."
On the one hand, it's difficult to justify the suggestion that the solution to dependence on pills... is more pills. Different pills, clearly, but still a pharmacological solution to a pharmacological (and psychological) problem. Welcome to 21st century medicine. Also troubling is how often we see Suboxone introduced without the weaning of the other opioid medications. We see this on cases PRIUM reviews. Sometimes, the doctor is choosing to prescribe Suboxone for chronic pain management (which represents off-label use, but is the doctor's right to do). Sometimes, the doctor intends to wean the other medications, but finds the patient unable or unwilling to participate in the weaning process. Why Suboxone isn't immediately discontinued in this scenario isn't clear, but we see if often enough that PRIUM's physician reviewers are clearly concerned about the appropriate use of this medication.
On the flip side, we do see cases here at PRIUM where Suboxone is used appropriately and successfully. And I personally know a few people that have been weaned off of very high dose narcotics successfully through the use of Suboxone.
Bottom line: If you see Suboxone on a claim, make absolutely sure that the physician is DATA 2000 certified and that the drug is being used appropriately. Close monitoring is key to a successful outcome.
Back to the web site for moment: www.turntohelp.com is actually a tremendous resource. Clearly, RB put a lot of time, effort, and study into crafting an easy to navigate, informative, balanced approach to the treatment of opioid dependence. Candidly, it took me about 10 minutes before I ended up on the Suboxone web site (I thought it would take less than a minute). The information on the site emphasizes the need for counseling and psychological support and goes to great lengths to discuss all available treatment options. RB is clearly not going for a direct sell of Suboxone, but rather counting on the fact that if more people seek treatment, some percentage may end up on Suboxone. There are plenty of other sites you can leverage to get the same information, but I've not found any as well organized or easy to navigate.
Certainly open to recommendations, though...
Michael
On Twitter @PRIUM1
Tuesday, July 17, 2012
CMS, Part D, and Opioids: A Familiar Approach
CMS has asked for additional public comment on its plan to improve drug utilization review for Medicare Part D participants. I'd provide a link to the memo, but it was emailed to me and I can't seem to locate the file on the CMS web site (go figure). If you really want to get your hands on it, let me know and I can email it to you.
Turns out, CMS has found that approximately 0.7% of the total Part D population (or about 225,000 beneficiaries) received more than 120 mg MED daily for at least 90 consecutive days in 2011. Kudos to CMS - not only for recognizing the clinical value of the 120 mg MED threshold, but also for citing the State of Washington's Department of Health as a source.
The current CMS approach has a lot going for it. (Candidly, it looks a lot like our process for addressing these claims, so no surprise that we're supportive). In summary, it calls for the following:
1) The Part D plan should have a documented policy for addressing overutilization of opioids.
2) There should be clinical triggers, defined by the plan, to flag certain beneficiaries for review.
3) Protocols should be developed to eliminate from review those beneficiaries with legitimate need for high dose opioid therapy (i.e., cancer diagnoses).
4) The plan should be prepared to communicate directly with prescribers of the opioid medications, both in writing and telephonically, to address patient safety concerns, medical appropriateness, and medical necessity. Further, the CMS approach calls for the conversation to be "clinician-to-clinician" (we would suggest a slightly more specific definition of "peer-to-peer", but CMS leaves that to the discretion of the individual plan).
5) The results of the intervention should be incorporated into future claims management decisions, most obviously via a beneficiary-level claim edit (what we would think of as a PBM prior auth or block on a particular medication).
6) Should a prescriber not cooperate, the CMS approach gives the plan the power to put such beneficiary-level claim edits in place to protect the patient's safety.
7) Some sort of case management activity is necessary to ensure future compliance.
Solid start.
How does this compare with your organization's approach?
Michael
On Twitter @PRIUM1
Turns out, CMS has found that approximately 0.7% of the total Part D population (or about 225,000 beneficiaries) received more than 120 mg MED daily for at least 90 consecutive days in 2011. Kudos to CMS - not only for recognizing the clinical value of the 120 mg MED threshold, but also for citing the State of Washington's Department of Health as a source.
The current CMS approach has a lot going for it. (Candidly, it looks a lot like our process for addressing these claims, so no surprise that we're supportive). In summary, it calls for the following:
1) The Part D plan should have a documented policy for addressing overutilization of opioids.
2) There should be clinical triggers, defined by the plan, to flag certain beneficiaries for review.
3) Protocols should be developed to eliminate from review those beneficiaries with legitimate need for high dose opioid therapy (i.e., cancer diagnoses).
4) The plan should be prepared to communicate directly with prescribers of the opioid medications, both in writing and telephonically, to address patient safety concerns, medical appropriateness, and medical necessity. Further, the CMS approach calls for the conversation to be "clinician-to-clinician" (we would suggest a slightly more specific definition of "peer-to-peer", but CMS leaves that to the discretion of the individual plan).
5) The results of the intervention should be incorporated into future claims management decisions, most obviously via a beneficiary-level claim edit (what we would think of as a PBM prior auth or block on a particular medication).
6) Should a prescriber not cooperate, the CMS approach gives the plan the power to put such beneficiary-level claim edits in place to protect the patient's safety.
7) Some sort of case management activity is necessary to ensure future compliance.
Solid start.
How does this compare with your organization's approach?
Michael
On Twitter @PRIUM1
Tuesday, July 10, 2012
FDA Plan on Opioids: Good News? Or Bad?
Today brought a tale of two headlines. Business Insurance declared "FDA Approves Plan to Fight Growing Opioid Abuse" while the New York Times declared "FDA Won't Order Doctors to Get Pain-Drug Training." Turns out, they're both right.
The FDA on Monday adopted the Risk Evaluation and Mitigation Strategy that has been debated, discussed, and deliberated for several years. The plan requires manufacturers of prescription opioids to, among other things, create and distribute physician and patient educational materials. That's not exactly a solution unto itself, but it does represent progress (and at least tacit acknowledgment on the part of the pharmaceutical industry that the misuse and abuse of prescription painkillers has become a national health crisis).
The controversial nature of the FDA announcement is driven largely by what is absent from the plan - mandatory physician training on the topic of safe opioid prescribing. In 2010, the FDA's own advisory panel rejected the notion that this plan should include "voluntary physician education," instead recommending that the such education should be mandatory. But the FDA has chosen to punt to Congress on this issue. The NY Times indicates that the FDA commissioner is "hopeful that Congress would eventually enact mandatory physician training."
In principle, I think this position is dangerous and not in keeping with the severity of the issue we face as a society. Pragmatically, however, I'm not certain the FDA has the authority (or perhaps more importantly, the enforcement capabilities) to create rules around mandatory physician education.
State medical boards and/or (I can't believe I'm writing this...) the US Congress need to step in and create both the mandate for physician training around opioid prescribing as well as the consequences for non-participation. This is more complicated than it might seem, but certainly a policy step necessary to stem the tide of opioid misuse and abuse.
Michael
On Twitter @PRIUM1
The FDA on Monday adopted the Risk Evaluation and Mitigation Strategy that has been debated, discussed, and deliberated for several years. The plan requires manufacturers of prescription opioids to, among other things, create and distribute physician and patient educational materials. That's not exactly a solution unto itself, but it does represent progress (and at least tacit acknowledgment on the part of the pharmaceutical industry that the misuse and abuse of prescription painkillers has become a national health crisis).
The controversial nature of the FDA announcement is driven largely by what is absent from the plan - mandatory physician training on the topic of safe opioid prescribing. In 2010, the FDA's own advisory panel rejected the notion that this plan should include "voluntary physician education," instead recommending that the such education should be mandatory. But the FDA has chosen to punt to Congress on this issue. The NY Times indicates that the FDA commissioner is "hopeful that Congress would eventually enact mandatory physician training."
In principle, I think this position is dangerous and not in keeping with the severity of the issue we face as a society. Pragmatically, however, I'm not certain the FDA has the authority (or perhaps more importantly, the enforcement capabilities) to create rules around mandatory physician education.
State medical boards and/or (I can't believe I'm writing this...) the US Congress need to step in and create both the mandate for physician training around opioid prescribing as well as the consequences for non-participation. This is more complicated than it might seem, but certainly a policy step necessary to stem the tide of opioid misuse and abuse.
Michael
On Twitter @PRIUM1
Monday, July 9, 2012
Connecticut Gets Drug Repackaging Right: Removing the Financial Incentive
I just reviewed the proposed language for Connecticut's rule change on repackaged drugs. Excellent piece of regulatory work, specifically because it includes all of the elements of an effective approach to mitigating the issue (and a road map for other states to follow):
1) The rule doesn't ban physician dispensing. There are legitimate reasons a doctor may need to dispense medications to a patient and this rule allows for those limited circumstances.
2) The rule focuses on the financial remuneration tied to physician dispensing and fixes such fees at the Average Wholesale Price (AWP) of the medication plus a reasonable dispensing fee ($5 for brand and $8 for generics).
3) The rule clearly specifies the source for the AWP (Medi-Span). Many states are silent to the AWP source and this creates a lot of noise in the system.
4) The rule specifies that fees are determined by "a) the NDC for the underlying drug product from the original manufacturer, or b) the therapeutic equivalent drug product from the original manufacturer/labeler NDC." This leaves no room for physicians or other agents to create new NDC codes as a result of repackaging.
5) If the underlying NDC isn't known or isn't shared, discretion rests with the payer to determine the most appropriate NDC code. There is a dispute resolution process outlined if the provider disagrees.
6) Perhaps most importantly, this is a regulatory change, not a statutory change. The laws of the state of CT allow the Work Comp Commission Chairman John Mastropietro to enact this rule change without legislative approval. This won't be possible in all states, but where it is, it's the way to go.
These are the five (and six, where possible) central tenants of an effective regulatory approach to repackaged drugs. Hopefully, we'll see this loophole closed state by state as soon as possible.
Michael
On Twitter @PRIUM1
1) The rule doesn't ban physician dispensing. There are legitimate reasons a doctor may need to dispense medications to a patient and this rule allows for those limited circumstances.
2) The rule focuses on the financial remuneration tied to physician dispensing and fixes such fees at the Average Wholesale Price (AWP) of the medication plus a reasonable dispensing fee ($5 for brand and $8 for generics).
3) The rule clearly specifies the source for the AWP (Medi-Span). Many states are silent to the AWP source and this creates a lot of noise in the system.
4) The rule specifies that fees are determined by "a) the NDC for the underlying drug product from the original manufacturer, or b) the therapeutic equivalent drug product from the original manufacturer/labeler NDC." This leaves no room for physicians or other agents to create new NDC codes as a result of repackaging.
5) If the underlying NDC isn't known or isn't shared, discretion rests with the payer to determine the most appropriate NDC code. There is a dispute resolution process outlined if the provider disagrees.
6) Perhaps most importantly, this is a regulatory change, not a statutory change. The laws of the state of CT allow the Work Comp Commission Chairman John Mastropietro to enact this rule change without legislative approval. This won't be possible in all states, but where it is, it's the way to go.
These are the five (and six, where possible) central tenants of an effective regulatory approach to repackaged drugs. Hopefully, we'll see this loophole closed state by state as soon as possible.
Michael
On Twitter @PRIUM1
Thursday, July 5, 2012
Purdue and GSK: Unintentional Irony in the Wall Street Journal
I'm still a little upset about the path Purdue Pharma is taking to extend patent exclusivity for Oxycontin for six additional months: testing in kids. The same day this hit the news (Tuesday), it was also reported that GlaxoSmithKline had agreed to plead guilty to charges of illegally marketing drugs and intentionally withholding safety data from US regulators.
Pages B2 and B3 of Tuesday's WSJ contain the two stories, virtually side by side. Excerpts from both:
B3: "Purdue hopes to gain six extra months next year of patent protection for Oxycontin by testing whether the powerful painkiller is safe for children."
B2: "The Justice Department says GSK improperly promoted some of its drugs from 1999 through 2010 for off-label uses. [One highlight from the government complaint]: Marketing Paxil, an antidepressant, as safe for children, despite trials that raised concerns about suicide. Example: Gave free samples to child psychiatrists."
Despite assurances from Purdue that the company doesn't promote the use of Oxycontin for children, I found the juxtaposition of these two stories both troubling and ironic.
Michael
On Twitter @PRIUM1
Pages B2 and B3 of Tuesday's WSJ contain the two stories, virtually side by side. Excerpts from both:
B3: "Purdue hopes to gain six extra months next year of patent protection for Oxycontin by testing whether the powerful painkiller is safe for children."
B2: "The Justice Department says GSK improperly promoted some of its drugs from 1999 through 2010 for off-label uses. [One highlight from the government complaint]: Marketing Paxil, an antidepressant, as safe for children, despite trials that raised concerns about suicide. Example: Gave free samples to child psychiatrists."
Despite assurances from Purdue that the company doesn't promote the use of Oxycontin for children, I found the juxtaposition of these two stories both troubling and ironic.
Michael
On Twitter @PRIUM1
Tuesday, July 3, 2012
Purdue Crosses the Line: Leave the Kids Alone
Front page of the Wall Street Journal this morning: "Purdue Pharma hopes to gain
six months of extra patent protection for OxyContin by testing whether the pain
killer is safe for children."
As I flipped to the article, I thought "this must be for terminally ill kids... because as sad as that would be, there's no way, in good conscience, they could test this stuff on kids otherwise."
I was wrong. The study will include subjects ages 6 to 16 in "moderate to severe pain." Purdue is attempting to take advantage of an FDA rule that allows for the extension of patent exclusivity merely for conducting studies in pediatric populations. The goal of the incentive is to help pediatric specialists understand the effect of a wide range of medications on children (which sounds like a good idea). In this case, Purdue is exploiting the FDA reg in order to rack up another $1 billion before OxyContin goes generic. It's despicable.
The very nature of FDA trials are short-term. The real danger here is the long term effects on the children that participate in the study (about 150 children will be included). What impact might this have on the future risk of addiction to opioids or other addictive substances? How will Purdue know? Are there requirements to track these kids as they grow into adulthood? Is the risk here really worth the "benefit," which will largely accrue to a pharmaceutical company in the form of additional revenues?
True, pediatric specialists will have more data on the drug's safety and efficacy profile in children... but so what? While we grapple, as a society, with the unintended consequences of opioid misuse - a problem the CDC has rightly labeled an "epidemic" - let's leave the kids out of it. Please.
Michael
On Twitter @PRIUM1
As I flipped to the article, I thought "this must be for terminally ill kids... because as sad as that would be, there's no way, in good conscience, they could test this stuff on kids otherwise."
I was wrong. The study will include subjects ages 6 to 16 in "moderate to severe pain." Purdue is attempting to take advantage of an FDA rule that allows for the extension of patent exclusivity merely for conducting studies in pediatric populations. The goal of the incentive is to help pediatric specialists understand the effect of a wide range of medications on children (which sounds like a good idea). In this case, Purdue is exploiting the FDA reg in order to rack up another $1 billion before OxyContin goes generic. It's despicable.
The very nature of FDA trials are short-term. The real danger here is the long term effects on the children that participate in the study (about 150 children will be included). What impact might this have on the future risk of addiction to opioids or other addictive substances? How will Purdue know? Are there requirements to track these kids as they grow into adulthood? Is the risk here really worth the "benefit," which will largely accrue to a pharmaceutical company in the form of additional revenues?
True, pediatric specialists will have more data on the drug's safety and efficacy profile in children... but so what? While we grapple, as a society, with the unintended consequences of opioid misuse - a problem the CDC has rightly labeled an "epidemic" - let's leave the kids out of it. Please.
Michael
On Twitter @PRIUM1
Monday, July 2, 2012
MMI and Narcotics: Can't Get There From Here
For those of you with access to the American Medical Association's "Guides Newsletter", check out the March/April 2011 issue. There's a great article entitled Prescription Narcotics: An Obstacle to Maximum Medical Improvement. (I'm actually not that behind in my reading... I was just given a copy of this particular article recently).
The article points out that there are "concerns that the obstables to MMI created by prescription narcotics will delay the resolution of claims (which could be harmful to the patient, as well as to other stakeholders). There is also concern that evaluators will confuse the effects of narcotics with permanent impairment and will consequently create erroneous impairment ratings."
The basic premise here is that narcotics expand the nature of a patient's impairment beyond pain. When one is on narcotics for a long period of time, MMI becomes nearly impossible to assess with any degree of accuracy.
We're starting to see some physicians justify chronic opioid therapy and refuse to respond to the evidence because "the patient is at MMI."
Challenge this presumption. It will benefit you and your claimant when you do.
Michael
On Twitter @PRIUM1
The article points out that there are "concerns that the obstables to MMI created by prescription narcotics will delay the resolution of claims (which could be harmful to the patient, as well as to other stakeholders). There is also concern that evaluators will confuse the effects of narcotics with permanent impairment and will consequently create erroneous impairment ratings."
The basic premise here is that narcotics expand the nature of a patient's impairment beyond pain. When one is on narcotics for a long period of time, MMI becomes nearly impossible to assess with any degree of accuracy.
We're starting to see some physicians justify chronic opioid therapy and refuse to respond to the evidence because "the patient is at MMI."
Challenge this presumption. It will benefit you and your claimant when you do.
Michael
On Twitter @PRIUM1
Thursday, June 28, 2012
Reducing Opioid Utilization: Feedback on IAIABC Model Legislation and Rules
[Submitted to IAIABC on June 28, 2012]
To Whom it May Concern:
On behalf of PRIUM, a URAC-accredited utilization review
company based in Duluth, GA, I’d like to commend the IAIABC on its efforts to
address the epidemic of prescription drug over-utilization in workers’ compensation
systems throughout the country. We have reviewed both the model statutory
language as well as the model regulatory language IAIABC developed and would
like to provide the following comments:
Regarding the model legislation, the critical components of
any state effort to stem the tide of prescription drug misuse appear to be
present. Treatment guidelines, PDMPs, dosage and duration limitations,
pre-authorization, appropriate billing for services, and dispute resolution
are, in fact, the essential elements of an effective statutory strategy to
address the issue. We see room for improvement, however, in the model
statutory language in two areas:
1) [Section
2: Treatment guidelines]: The current language leaves far too much latitude for
states to develop consensus-based guidelines (vs. evidence-based
guidelines). We recognize the use of the term “evidence based” in the
model language, but left open to the whims of state politics, medical boards,
and lobbying efforts from the pharmaceutical and medical device industries, a
state might be left with relatively weak, ineffectual medical treatment
guidelines that allow status quo prescribing patterns to continue
unabated. As an alternative, we suggest one of two approaches:
a.
Define the treatment guidelines to be adopted
within the statutory language itself (as opposed to leaving it to the state
agency to determine); or
b.
Provide a more thorough definition of
appropriate medical treatment guidelines, perhaps through a series of criteria
that must be met. Such criteria might include requirements that the
medical treatment guidelines:
i.
Rely on specified, comprehensive, systematic
review of medical literature;
ii.
Include transparent criteria for rating the
strength of evidence, including individual medical studies;
iii.
Remain current and incorporate contemporary
studies;
iv.
Address frequency, duration, intensity, and
appropriateness of treatment;
v.
Have been adopted by at least one other state.
2) [Section
6: Prohibition]: The use of the word “may” in connection with preauthorization
is troubling. In some states, the preauthorization process is viewed by
physicians as contentious and antagonistic. PRIUM advocates the use of
preauthorization procedures if, and only if, the treating physician refuses to
engage in collegial discussion or respond to the medical evidence when it is
presented to him/her by a peer. Nevertheless, should a treating physician
prove unresponsive to the evidence, we believe statutory language should
provide more stringent protocols for addressing such issues. We also find
the limit in Section 6 to “specific forms of opioids” far too narrow to address
the overarching issue the industry currently faces. We suggest the
following: “The Agency shall grant the insurance carrier the right to require
preauthorization for any medications being prescribed that do not appear to
meet the standard of care established by the medical treatment
guidelines.”
Regarding the model rules, the translation from statute to
regulatory approach is well defined. We found the “drafting notes” to be
particularly helpful in guiding lawmakers in the development of these critical
rules. There are a few areas, however, that we believe require more
nuanced thinking prior to launching the regulatory model:
1) [Section
1, (3): Effective Date]: Our industry learned a valuable lesson from the
creation, adoption, and implementation of the Texas Closed Formulary
Rules. Texas implemented these new rules in two stages: starting 9/1/11
for all new injuries as of that date, and starting 9/1/13 for all “legacy”
claims, effectively providing a two year remediation period for the insurance
carriers and treating physicians to address difficult cases in preparation for
the 9/1/13 requirement for preauthorization of all N drugs. This is smart
public policy. Contrast this with New York where adoption of medical
treatment guidelines as of a single, “line in the sand” effective date has
created a judicial and legislative battle that has yet to resolve itself.
On the one hand, a single effective date creates chaos as carriers and
physicians try to figure out how to address legacy claims, which tend to be
extremely complicated. On the other hand, only applying new rules to new
injuries creates two standards of care within a workers’ compensation system, where
an injured worker’s treatment plan is driven entirely by the date on which they
were injured (which makes no clinical sense). We recommend model
regulatory language that mirrors the Texas Closed Formulary approach – an
initial implementation date for new injuries, followed by a remediation period
for legacy claims, followed by a fully effective date for new rules and all
claims.
2) [Section
7: Continuing Education]: We understand that there was a lively discussion on
your most recent conference call regarding the mandated education component of
the model rules. Our view is that the absolute onslaught of marketing
dollars spent by the pharmaceutical industry to “educate” doctors should, in
fact must, be countered by mandated, unbiased continuing education focused on
the risks associated with chronic opioid therapy. In 2011, the
pharmaceutical industry generated $11 billion from the sale of opioids, a full
$3 billion just from Oxycontin. The #1 source of information for
physicians regarding these drugs remains the drug company sales
representative. This must change. PRIUM is disappointed that state
medical societies and the American Medical Association are opposed to such
measures. We strongly recommend that IAIABC remain committed to mandated
continuing education.
3) [Section
10, Preauthorization Required]: PRIUM believes that the best possible way to
eliminate the over-utilization of prescription drugs in workers’ compensation
is to engage the treating physician in the creation of a revised treatment plan.
Mandated preauthorization should not be the first step taken by an insurance
carrier when a particular claim is brought under scrutiny due to the
prescription medication regimen. That being said, if the treating
physician refuses to participate in the creation of a revised treatment plan
and continues to prescribe, in some cases, dangerous levels of medications,
mandated preauthorization can be a powerful tool to protect patient safety and
ensure positive clinical outcomes.
We appreciate the opportunity to provide this feedback and
commend IAIABC for the transparency and collaboration that have been emblematic
of this process thus far.
Respectfully submitted,
Michael Gavin
Chief Strategy Officer
PRIUM
Michael Gavin - Chief
Strategy Officer
2805 Peachtree Industrial Blvd.
Suite 112
Duluth, GA 30097
Direct Line: 678-735-7305
Toll Free: 888-588-4964 x104
Cell: 678-458-8216 Fax: 678-736-6585
Website: www.prium.net
Twitter: @PRIUM1
Friday, June 22, 2012
Joe Paduda Hosts Health Wonk Review
Thanks for including Evidence Based!
http://www.joepaduda.com/archives/002358.html
On Twitter @PRIUM1
http://www.joepaduda.com/archives/002358.html
On Twitter @PRIUM1
Wednesday, June 20, 2012
The Medical/Legal Summit: Why Isn't Everyone Doing This?
I was privileged last week to spend a few days in Charlotte, NC with Arrowpoint Capital. Julie Fortune, Chief Claims Officer, and her team put together a Medical/Legal Summit in hopes of educating, coordinating, and enhancing the medical management and litigation management of their claims. They pulled together about 120 people including internal claims adjusters, litigation managers, outside vendors, outside legal counsel (from many different jurisdictions), medical experts, and even invited an Arrowpoint actuary (all joking aside, Rich gave a great presentation on the importance of historical cost data to actuaries).
Topics focused on chronic pain management, appropriate use of prescription drug therapy, alternative treatment pathways, Medicare and secondary payment rules, case management, proper use of investigative services, changing rules and regulations at the state level, and how best to use clinical resources like doctors, nurses, and pharmacists.
And this wasn't summer camp, folks. This was an intense conference that started promptly at 8:00 am each morning and lasted well into the night as attendees worked on a rather complicated case study. The Arrowpoint leadership team divided their employees and all of the outside attorneys into eight case teams and had each team present at the end of the conference, incorporating all that they had learned during the course of the conference. And everyone had to present. No free riders. You had to pay attention and really show that you "got it".
Arrowpoint is managing run-off claims, but every payer has a subset of claims that require high levels of coordination amongst many parties, internally and externally, in order to achieve positive outcomes (clinically and legally). And one of my key take-aways from the Summit is how closely those two strategies - clinical and legal - need to be linked.
Does your organization pull together an annual Medical/Legal Summit? If not, why not? This is the sort of education and coordination our industry needs.
Let's get to work.
Michael
On Twitter @PRIUM1
Topics focused on chronic pain management, appropriate use of prescription drug therapy, alternative treatment pathways, Medicare and secondary payment rules, case management, proper use of investigative services, changing rules and regulations at the state level, and how best to use clinical resources like doctors, nurses, and pharmacists.
And this wasn't summer camp, folks. This was an intense conference that started promptly at 8:00 am each morning and lasted well into the night as attendees worked on a rather complicated case study. The Arrowpoint leadership team divided their employees and all of the outside attorneys into eight case teams and had each team present at the end of the conference, incorporating all that they had learned during the course of the conference. And everyone had to present. No free riders. You had to pay attention and really show that you "got it".
Arrowpoint is managing run-off claims, but every payer has a subset of claims that require high levels of coordination amongst many parties, internally and externally, in order to achieve positive outcomes (clinically and legally). And one of my key take-aways from the Summit is how closely those two strategies - clinical and legal - need to be linked.
Does your organization pull together an annual Medical/Legal Summit? If not, why not? This is the sort of education and coordination our industry needs.
Let's get to work.
Michael
On Twitter @PRIUM1
Monday, June 18, 2012
PDMPs: NY Sets the Standard, MO Lags Behind
Prescription Drug Monitoring Programs (PDMPs) are an essential tool for combatting the inappropriate use of prescription drugs. New York has put in place legislation that may serve as a model for how best to design and implement such a program.
The bill calls for mandatory electronic communication of prescriptions between doctors and pharmacies within three years, real time tracking of prescriptions, and required record checks before doctors write new scripts for certain medications, including opioids.
Of course, state level efforts can only have so much impact. Doctor shopping across borders is becoming increasingly common and right now, no single database contains sufficient information to help prevent inappropriate prescriptions on an interstate basis. I understand there is some nascent movement toward establishing such a database, but my quick research didn't yield anything substantial.
And congrats to New Hampshire for finally getting its act together. NH is the 49th state to establish a PDMP program. The "Live Free of Die" crowd certainly fought against it, even winning a provision that data would be deleted after 6 months (unless abuse is expected). We'll take what we can get.
The lone hold out? Missouri. The "Show Me" state needs to show us they're serious about prescription drug abuse. Might be an uphill battle, though. Here's a quote from Missouri State Senator Rob Shaaf (R-St. Joseph), a family physician, after the passage of a PDMP bill in March of this year (which appears to have stalled in committee back in May): "Letting the government have your very personal and sensitive medical information on a government database, it's just wrong and Big Brother shouldn't have that effect on our lives... this is liberty versus safety."
Yeah... drug addicts should be free to doctor shop as much as they wish without fear of detection or consequence. And drug seekers throughout the midwest should feel equally free to flood into Missouri seeking prescription drugs. Not exactly enlightened public policy, but so what if the preservation of liberty makes Missouri the nation's capital for prescription drug abuse?
Liberty has its bounds, Dr. Schaaf, and you're on the wrong side of this one.
Michael
On Twitter @PRIUM1
The bill calls for mandatory electronic communication of prescriptions between doctors and pharmacies within three years, real time tracking of prescriptions, and required record checks before doctors write new scripts for certain medications, including opioids.
Of course, state level efforts can only have so much impact. Doctor shopping across borders is becoming increasingly common and right now, no single database contains sufficient information to help prevent inappropriate prescriptions on an interstate basis. I understand there is some nascent movement toward establishing such a database, but my quick research didn't yield anything substantial.
And congrats to New Hampshire for finally getting its act together. NH is the 49th state to establish a PDMP program. The "Live Free of Die" crowd certainly fought against it, even winning a provision that data would be deleted after 6 months (unless abuse is expected). We'll take what we can get.
The lone hold out? Missouri. The "Show Me" state needs to show us they're serious about prescription drug abuse. Might be an uphill battle, though. Here's a quote from Missouri State Senator Rob Shaaf (R-St. Joseph), a family physician, after the passage of a PDMP bill in March of this year (which appears to have stalled in committee back in May): "Letting the government have your very personal and sensitive medical information on a government database, it's just wrong and Big Brother shouldn't have that effect on our lives... this is liberty versus safety."
Yeah... drug addicts should be free to doctor shop as much as they wish without fear of detection or consequence. And drug seekers throughout the midwest should feel equally free to flood into Missouri seeking prescription drugs. Not exactly enlightened public policy, but so what if the preservation of liberty makes Missouri the nation's capital for prescription drug abuse?
Liberty has its bounds, Dr. Schaaf, and you're on the wrong side of this one.
Michael
On Twitter @PRIUM1
Wednesday, June 13, 2012
The Battle Over Hydrocodone: Revisited
This blog, first and foremost, is intended to be informative and educational. My goal has always been to cast about with opinions and the allow others to offer feedback, guidance, and perspective.
Such has been the case since I advocated for moving hydrocodone-containing medications from schedule III to schedule II. On Monday, I wrote about the controversy regarding a provision drafted by Sen. Joe Manchin (D - WV) that would provide for such a reclassification.
In response to that post, I heard from several pharmacists that disagreed with my position.
First, it was pointed out that hydrocodone-acetaminophen is an acute medication and changing it to a schedule II drug may inhibit access to patients that need it quickly. I pointed out that data suggests the drug is often used for chronic pain management, too. That brought this response from a pharmacist: "Hydrocodone is often used chronically, although it is often for breakthrough pain and often with a long acting opioid. Hydrocodone/APAP would not be the sole pain medication. Data from a large carrier in Q4 2011 shows 14% of mature patients using hydrocodone (3 years or older) are using it with a long acting opioid."
Another issue, perhaps more relevant to the battle over abuse and addiction of prescription drugs: "Reclassifying hydrocodone/apap products as a CII does not address the inappropriate and over prescribing of this medication and opioids in general. All it will do is create undue burden on pharmacists and patients without addressing the real problem. Physicians generally do not care how much work or regulatory hoops pharmacists have to jump through to fill a prescription." Good point.
What we all decided to agree upon, though, is the fact that Zohydro (a single ingredient hydrocodone drug as a controlled release long acting opioid - currently pending FDA approval) should be a schedule II drug.
Thanks to all for the input.
Michael
On Twitter @PRIUM1
Such has been the case since I advocated for moving hydrocodone-containing medications from schedule III to schedule II. On Monday, I wrote about the controversy regarding a provision drafted by Sen. Joe Manchin (D - WV) that would provide for such a reclassification.
In response to that post, I heard from several pharmacists that disagreed with my position.
First, it was pointed out that hydrocodone-acetaminophen is an acute medication and changing it to a schedule II drug may inhibit access to patients that need it quickly. I pointed out that data suggests the drug is often used for chronic pain management, too. That brought this response from a pharmacist: "Hydrocodone is often used chronically, although it is often for breakthrough pain and often with a long acting opioid. Hydrocodone/APAP would not be the sole pain medication. Data from a large carrier in Q4 2011 shows 14% of mature patients using hydrocodone (3 years or older) are using it with a long acting opioid."
Another issue, perhaps more relevant to the battle over abuse and addiction of prescription drugs: "Reclassifying hydrocodone/apap products as a CII does not address the inappropriate and over prescribing of this medication and opioids in general. All it will do is create undue burden on pharmacists and patients without addressing the real problem. Physicians generally do not care how much work or regulatory hoops pharmacists have to jump through to fill a prescription." Good point.
What we all decided to agree upon, though, is the fact that Zohydro (a single ingredient hydrocodone drug as a controlled release long acting opioid - currently pending FDA approval) should be a schedule II drug.
Thanks to all for the input.
Michael
On Twitter @PRIUM1
Tuesday, June 12, 2012
BCBS of Mass: Tough New Policy on Opioid Scripts
Blue Cross Blue Shield of Massachusetts is deploying a new policy regarding opioid scripts beginning on July 1. Physicians will be restricted from writing more than a 30 days supply of powerful painkillers without a mandatory review by BCBS.
This is a "first of its kind" policy in commercial/group health (as far as I can tell), though the concept isn't foreign to us in work comp. The issue of prescription drug abuse is pervasive and I'm pleased to see BCBS of MA take this bold step.
Yes, this is going to create some additional administrative burden and expense for physicians. Those concerns are legitimate. Unfortunately, the societal cost of abuse and addiction are sufficiently high that policies such as this are necessary.
Michael
On Twitter @PRIUM1
This is a "first of its kind" policy in commercial/group health (as far as I can tell), though the concept isn't foreign to us in work comp. The issue of prescription drug abuse is pervasive and I'm pleased to see BCBS of MA take this bold step.
Yes, this is going to create some additional administrative burden and expense for physicians. Those concerns are legitimate. Unfortunately, the societal cost of abuse and addiction are sufficiently high that policies such as this are necessary.
Michael
On Twitter @PRIUM1
Monday, June 11, 2012
The Battle Over Hydrocodone: Pharmacists Take a Surprising Stand
US Senator Joe Manchin (D - WV) has authored a piece of legislation that would reschedule hydrocodone from schedule III to schedule II (via an amendment to the Prescription Drug User Fee Act). This sounds simple enough and enjoys bipartisan support on the Hill.
1) Most claims people (and even many clinical people) think hydrocodone is already a schedule II drug.
2) There's no doubt that hydrocone-containing products are dangerous, come with significant risk of addiction, and should be better controlled than they currently are.
3) This represents an opportunity for politicians and regulators to show that they're at least willing to take some easy steps to stem the tide of prescription drug over-utilization and abuse in this country.
You would think, at least.
A letter was sent last week to all members of the House and Senate from five aligned groups that have two things in common: first, they are either made up of or represent pharmacists; and second, they don't want to see this bill pass. The groups? The American Pharmacists Association, Food Marketing Institute, International Academy of Compounding Pharmacists (really?), National Association of Chain Drug Stores, and National Pharmacists Association.
The letter states, in part:
“We understand the concerns about diversion and abuse of these products and we share these concerns. Nevertheless, moving all of these hydrocodone products to Schedule II will result in significant barriers for patients who have a legitimate need for these products, and it will result in adding to the nation’s healthcare costs with no assurance of a reduction in diversion and abuse.”
That is absolutely wrong headed.
What are the practical implications of moving hydrocodone products to schedule II?
- They can't be prescribed as easily physicians and some states restrict NPs and PAs from precribing schedule II drugs at all.
- The drugs will become more costly for pharmacies to obtain and inventory will become more expensive to manage (given the stringent storage and inventory assessment requirements).
Making hydrocodone harder to obtain WILL NOT impact patients that truly need the drugs. The real issue here is that pharmacy margins, already thin, are going to take a hit. I acknowledge this is a real economic issue and an unfortunate unintended consequence of doing the right thing.
Michael
On Twitter @PRIUM1
1) Most claims people (and even many clinical people) think hydrocodone is already a schedule II drug.
2) There's no doubt that hydrocone-containing products are dangerous, come with significant risk of addiction, and should be better controlled than they currently are.
3) This represents an opportunity for politicians and regulators to show that they're at least willing to take some easy steps to stem the tide of prescription drug over-utilization and abuse in this country.
You would think, at least.
A letter was sent last week to all members of the House and Senate from five aligned groups that have two things in common: first, they are either made up of or represent pharmacists; and second, they don't want to see this bill pass. The groups? The American Pharmacists Association, Food Marketing Institute, International Academy of Compounding Pharmacists (really?), National Association of Chain Drug Stores, and National Pharmacists Association.
The letter states, in part:
“We understand the concerns about diversion and abuse of these products and we share these concerns. Nevertheless, moving all of these hydrocodone products to Schedule II will result in significant barriers for patients who have a legitimate need for these products, and it will result in adding to the nation’s healthcare costs with no assurance of a reduction in diversion and abuse.”
That is absolutely wrong headed.
What are the practical implications of moving hydrocodone products to schedule II?
- They can't be prescribed as easily physicians and some states restrict NPs and PAs from precribing schedule II drugs at all.
- The drugs will become more costly for pharmacies to obtain and inventory will become more expensive to manage (given the stringent storage and inventory assessment requirements).
Making hydrocodone harder to obtain WILL NOT impact patients that truly need the drugs. The real issue here is that pharmacy margins, already thin, are going to take a hit. I acknowledge this is a real economic issue and an unfortunate unintended consequence of doing the right thing.
Michael
On Twitter @PRIUM1
Thursday, June 7, 2012
New Health Wonk Review
Check it out. Thanks to Maggie Mahar for including Evidence Based.
http://www.healthinsurance.org/blog/2012/06/07/health-wonk-review/
On Twitter @PRIUM1
http://www.healthinsurance.org/blog/2012/06/07/health-wonk-review/
On Twitter @PRIUM1
Wednesday, June 6, 2012
NCCI Narcotics Report: The More You Get... The More You Get
Of all the interesting statistics contained in the new NCCI research brief, the one that stood out most to me was the section entitled "Early Narcotic Use Is Indicative of Prolonged Use." Turns out, the earlier one gets narcotics and the higher the dose one receives... the longer one will likely be on the drugs and the higher the dose will likely be.
If ever there was an analysis that supported early intervention on claims where narcotics are being utilized, this is it. Most of us have felt this intuitively, but this is the first analysis I've seen detailing the extent of the issue.
Some highlights:
- Shockingly, about 10% of claimants receive > 825 mg MED in the first quarter following injury. 50% of all claims receive between 100 mg MED and 370 mg MED in the first quarter following injury. Recall the 120 mg MED threshold from my post earlier this week. That's a monthly metric, not quarterly... but I was still surprised at the prevalence of high doses of narcotics early in the claim life.
- 63% of claimants with MED > 825 mg in the initial quarter following injury continued to receive narcotics in the second quarter following injury. Only 35% of claimants receiving between 370 mg and 825 mg MED in the first quarter post-injury continue to receive narcotics in the next quarter.
- The graphics NCCI put together on this topic are compelling. Check out Exhibits 8 and 9. Once a claimant is on high doses of narcotics, that claimant is highly likely to remain on high doses of the drugs. For the 10% of claimants that start out on > 825 mg MED, the average MED in the first quarter post-injury appears to be in the range of 2,000 mg MED (or approximately 650-700 mg MED per month). By the 20th quarter post injury, this cohort averages around 7,000 mg MED (or over 2,000 mg MED per month).
This is unfathomable. And it begs the obvious question for further analysis: What is the death rate, by quarter, in the > 825 mg MED cohort?
Michael
On Twitter @PRIUM1
If ever there was an analysis that supported early intervention on claims where narcotics are being utilized, this is it. Most of us have felt this intuitively, but this is the first analysis I've seen detailing the extent of the issue.
Some highlights:
- Shockingly, about 10% of claimants receive > 825 mg MED in the first quarter following injury. 50% of all claims receive between 100 mg MED and 370 mg MED in the first quarter following injury. Recall the 120 mg MED threshold from my post earlier this week. That's a monthly metric, not quarterly... but I was still surprised at the prevalence of high doses of narcotics early in the claim life.
- 63% of claimants with MED > 825 mg in the initial quarter following injury continued to receive narcotics in the second quarter following injury. Only 35% of claimants receiving between 370 mg and 825 mg MED in the first quarter post-injury continue to receive narcotics in the next quarter.
- The graphics NCCI put together on this topic are compelling. Check out Exhibits 8 and 9. Once a claimant is on high doses of narcotics, that claimant is highly likely to remain on high doses of the drugs. For the 10% of claimants that start out on > 825 mg MED, the average MED in the first quarter post-injury appears to be in the range of 2,000 mg MED (or approximately 650-700 mg MED per month). By the 20th quarter post injury, this cohort averages around 7,000 mg MED (or over 2,000 mg MED per month).
This is unfathomable. And it begs the obvious question for further analysis: What is the death rate, by quarter, in the > 825 mg MED cohort?
Michael
On Twitter @PRIUM1
Subscribe to:
Posts (Atom)